Hattenbach Lars-Olof, Grisanti Salvatore, Feltgen Nicolas, Chronopoulos Argyrios
Augenklinik des Klinikums Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland.
Augenklinik der Universitätsmedizin Lübeck, Lübeck, Deutschland.
Ophthalmologe. 2020 Sep;117(9):848-857. doi: 10.1007/s00347-020-01192-5.
Subretinal hemorrhage involving the macula is a typical complication in a variety of retinal diseases, whereby age-related macular degeneration (AMD) is by far the leading cause.
A literature search was carried out in PubMed.
Numerous studies have demonstrated the effectiveness of various approaches to the management of submacular hemorrhage, including intravitreal anti-VEGF treatment, pneumatic displacement supported by fibrinolytic agents or surgical drainage.
There is currently no consensus regarding evidence-based standard treatment for macular hemorrhage, although there is a trend towards minimally invasive approaches. Regardless of the choice of the primary treatment approach, the time to treatment and an accompanying intravitreal treatment with VEGF inhibitors are decisive for the functional outcome.
累及黄斑的视网膜下出血是多种视网膜疾病的典型并发症，其中年龄相关性黄斑变性（AMD）是迄今为止的主要病因。
在PubMed上进行文献检索。
大量研究表明了各种治疗黄斑下出血方法的有效性，包括玻璃体内抗VEGF治疗、纤维蛋白溶解剂辅助的气体置换或手术引流。
目前对于黄斑出血的循证标准治疗尚无共识，尽管存在向微创方法发展的趋势。无论选择何种主要治疗方法，治疗时机以及同时进行的玻璃体内VEGF抑制剂治疗对功能预后起着决定性作用。
Zotero 插件